Serving the Society Since 1986
Advanced Search
Volume 33 Issue 6
December 2018
    Citation: Jia Liu, Wen Pan, Dongliang Yang. The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection—A Mini Comment on the 2018 Medicine Nobel Prize .VIROLOGICA SINICA, 2018, 33(6) : 467-471.  http://dx.doi.org/10.1007/s12250-018-0077-3
    shu

    The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection—A Mini Comment on the 2018 Medicine Nobel Prize

    cstr: 32224.14.s12250-018-0077-3
    • 1.

      Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

    • Corresponding author: Jia Liu, jialiu77@hust.edu.cn, ORCID: http://orcid.org/0000-0002-8262-4997
    • Received Date: 26 October 2018
      Accepted Date: 11 December 2018
      Published Date: 20 December 2018
      Available online: 01 December 2018
    • The 2018 Medicine Nobel Prize was awarded jointly to two immunologists, James P. Allison at the University of Texas MD Anderson Cancer Center in Houston and Tasuku Honjo at Kyoto University in Japan, who pioneered a new way to treat cancers (Ledford et al. 2018). Both Laureates have shown how so called "immune checkpoints" on T cells can be used to manipulate the immune responses so that T cells can efficiently attack cancer cells. Using the immune system to fight cancers has been investigated for more than a 100 years. Recent advances in cancer immunotherapy, particularly immune checkpoint blockade therapy have dramatically changed the therapeutic strategy against advanced cancers. Through inhibiting negative immune regulation, these approaches have demonstrated improved overall survival for patients with advanced cancers. Importantly, for some of the patients treated with such strategies, their tumors seem to totally disappear.
    • 加载中

      1. Akhmetzyanova I, Drabczyk M, Neff CP, Gibbert K, Dietze KK, Werner T, Liu J, Chen L, Lang KS, Palmer BE, Dittmer U, Zelinskyy G (2015) PD-L1 expression on retrovirus-infected cells mediates immune escape from CD8+ T cell killing. PLoS Pathog 11:e1005224
          doi: 10.1371/journal.ppat.1005224

      2. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R (2006) Restoring function in exhausted CD8+ T cells during chronic viral infection. Nature 439:682–687
          doi: 10.1038/nature04444

      3. Bengsch B, Martin B, Thimme R (2014) Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 61:1212–1219
          doi: 10.1016/j.jhep.2014.07.005

      4. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81:4215–4225
          doi: 10.1128/JVI.02844-06

      5. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010) Phase Ⅰ study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175
          doi: 10.1200/JCO.2009.26.7609

      6. Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK (2018) Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Investig 128:4588–4603
          doi: 10.1172/JCI121960

      7. Channappanavar R, Twardy BS, Suvas S (2012) Blocking of PDL-1 interaction enhances primary and secondary CD8+ T cell response to herpes simplex virus-1 infection. PLoS ONE 7:e39757
          doi: 10.1371/journal.pone.0039757

      8. Dietze KK, Zelinskyy G, Liu J, Kretzmer F, Schimmer S, Dittmer U (2013) Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virusspecific CD8+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog 9:e1003798
          doi: 10.1371/journal.ppat.1003798

      9. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini EM, Andreone P, Missale G, Ferrari C (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138:682–693, 693 e681–684
          doi: 10.1053/j.gastro.2009.09.052

      10. Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui A, Ahmed R, Walker CM (2013) Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA 110:15001–15006
          doi: 10.1073/pnas.1312772110

      11. Gane E, Gaggar A, Nguyen AH, Subramanian GM, McHutchison JG, Schwabe C, Dunbar R (2017) A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients. J Hepatol 66:S26–S27

      12. Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I (2013) A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS ONE 8:e63818
          doi: 10.1371/journal.pone.0063818

      13. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K- (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028
          doi: 10.1056/NEJMoa1501824

      14. Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM, Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, Eron JJ, Team ACTS (2017) Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. J Infect Dis 215:1725–1733
          doi: 10.1093/infdis/jix191

      15. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144
          doi: 10.1056/NEJMoa1305133

      16. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
          doi: 10.1056/NEJMoa1003466

      17. Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai WP, Heraud JM, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G (2006) CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 108:3834–3842
          doi: 10.1182/blood-2006-04-010637

      18. Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895
          doi: 10.1002/embj.1992.11.issue-11

      19. Jeon S, Rowe AM, Carroll KL, Harvey SAK, Hendricks RL (2018) PD-L1/B7-H1 inhibits viral clearance by macrophages in HSV-1-infected corneas. J Immunol 200:3711–3719
          doi: 10.4049/jimmunol.1700417

      20. Kaufmann DE, Walker BD (2009) PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 182:5891–5897
          doi: 10.4049/jimmunol.0803771

      21. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459–465
          doi: 10.1084/jem.182.2.459

      22. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP (1997) Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 94:8099–8103
          doi: 10.1073/pnas.94.15.8099

      23. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736
          doi: 10.1126/science.271.5256.1734

      24. Ledford H, Else H, Warren M (2018) Cancer immunologists scoop medicine Nobel prize. Nature 562:20–21

      25. Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, Moller I, Seiz P, Glebe D, Wang B, Yang D, Lu M, Roggendorf M (2014) Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 10:e1003856
          doi: 10.1371/journal.ppat.1003856

      26. Palmer BE, Neff CP, Lecureux J, Ehler A, Dsouza M, RemlingMulder L, Korman AJ, Fontenot AP, Akkina R (2013) In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol 190:211–219
          doi: 10.4049/jimmunol.1201108

      27. Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, Pavlik DF, Rodriguez-Garcia M, Pereyra F, Freeman GJ, Kavanagh DG, Kaufmann DE (2011) Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 118:965–974
          doi: 10.1182/blood-2010-12-328070

      28. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558–562
          doi: 10.1038/nature13904

      29. Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov N, Fletcher S, Kennedy PT, Bertoletti A (2018) PD-1 blockade partially recovers dysfunctional virusspecific B cells in chronic hepatitis B infection. J Clin Investig 128:4573–4587
          doi: 10.1172/JCI121957

      30. Sanmamed MF, Chen L (2018) A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175:313–326
          doi: 10.1016/j.cell.2018.09.035

      31. Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, Nebbia G, Kennedy PT, Geretti AM, Dusheiko G, Maini MK (2011) Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53:1494–1503
          doi: 10.1002/hep.24249

      32. Seung E, Dudek TE, Allen TM, Freeman GJ, Luster AD, Tager AM (2013) PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLoS ONE 8:e77780

      33. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020–1030
          doi: 10.1200/JCO.2013.53.0105

      34. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH, Chennareddi L, Silvestri G, Freeman GJ, Ahmed R, Amara RR (2009) Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458:206–210
          doi: 10.1038/nature07662

      35. Wykes MN, Lewin SR (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18:91–104

      36. Zhang E, Zhang X, Liu J, Wang B, Tian Y, Kosinska AD, Ma Z, Xu Y, Dittmer U, Roggendorf M, Yang D, Lu M (2011) The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection. PLoS ONE 6:e26196
          doi: 10.1371/journal.pone.0026196

    • 加载中

    Tables(2)

    PDF

    Article Metrics

    Article views(8616) PDF downloads(22) Cited by()

    Related
    Proportional views

      The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection—A Mini Comment on the 2018 Medicine Nobel Prize

        Corresponding author: Jia Liu, jialiu77@hust.edu.cn
      • 1. Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
      • Received Date: 26 October 2018
      • Accepted Date: 11 December 2018
      • Published Date: 20 December 2018

      Abstract: The 2018 Medicine Nobel Prize was awarded jointly to two immunologists, James P. Allison at the University of Texas MD Anderson Cancer Center in Houston and Tasuku Honjo at Kyoto University in Japan, who pioneered a new way to treat cancers (Ledford et al. 2018). Both Laureates have shown how so called "immune checkpoints" on T cells can be used to manipulate the immune responses so that T cells can efficiently attack cancer cells. Using the immune system to fight cancers has been investigated for more than a 100 years. Recent advances in cancer immunotherapy, particularly immune checkpoint blockade therapy have dramatically changed the therapeutic strategy against advanced cancers. Through inhibiting negative immune regulation, these approaches have demonstrated improved overall survival for patients with advanced cancers. Importantly, for some of the patients treated with such strategies, their tumors seem to totally disappear.

        HTML